Last reviewed · How we verify
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
Sofosbuvir and velpatasvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5B polymerase and NS5A protein, respectively.
Sofosbuvir and velpatasvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5B polymerase and NS5A protein, respectively. Used for Chronic hepatitis C virus (HCV) infection, all genotypes (1-6), with or without cirrhosis.
At a glance
| Generic name | Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] |
|---|---|
| Also known as | Epclusa |
| Sponsor | Ohio State University |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B polymerase and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Velpatasvir is an NS5A inhibitor that blocks a multifunctional viral protein essential for HCV replication and virion assembly. Together, this combination directly targets two critical steps in the HCV life cycle, achieving high cure rates across multiple HCV genotypes.
Approved indications
- Chronic hepatitis C virus (HCV) infection, all genotypes (1-6), with or without cirrhosis
Common side effects
- Headache
- Fatigue
- Diarrhea
- Nausea
- Insomnia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: